BIO Seeks ‘Substantial Runway’ To Shift Away From China As Momentum For Manfacturing Bill Grows

Association CEO John Crowley tells the Pink Sheet that a survey which found decoupling from China could be disruptive underscores the need to do so because having the supply chain ‘tied up with a global adversary is profoundly worrying to all of us.’

United States Capitol Building at sunset - Washington, DC, USA - Image
Next stop for the BIOSECURE legislation is a House Oversight Committee markup on 15 May. • Source: Shutterstock

As legislation that would force drug companies to stop using Chinese development and manufacturing contractors goes to a markup in the US House next week, the Biotechnology Innovation Organization has released an industry survey that found decoupling could be significantly disruptive.

BIO is hoping the results will help persuade lawmakers to provide a “substantial runway to begin and implement the decoupling...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Manufacturing

More from Compliance